Skip to main content

Table 2 Accessibility and prescription of EMA-approved OMPs for HMDs in the 18 individual MetabERN participating countries

From: Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network

  1. * All EU patients were registered in the NL in 2018
  2. ** Marketing authorization under discussion
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172